Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 11/20 | 0.72 |
| ▸ | PIM2 | Q9P1W9 | 10/20 | 0.72 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.72 |
| ▸ | HPGD | P15428 | 4/20 | 0.70 |
| ▸ | MAOA | P21397 | 3/20 | 0.70 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.70 |
| ▸ | GSK3B | P49841 | 2/20 | 0.70 |
| ▸ | RAB9A | P51151 | 2/20 | 0.70 |
| ▸ | MAOB | P27338 | 2/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.70 |
| ▸ | CISD1 | Q9NZ45 | 3/20 | 0.68 |
| ▸ | IGF1R | P08069 | 2/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1125013 | 1.00 | PIM1 (0.72) | PIM1PIM2PIM3HPGDMAOA | |
| SCHEMBL1125015 | 1.00 | PIM1 (0.72) | PIM1PIM2PIM3HPGDMAOA | |
| Benzaldehyde SCHEMBL10480890 | 0.93 | PIM1 (0.86) | PIM1PIM2PIM3HPGDMAOA | |
| Benzaldehyde SCHEMBL10480742 | 0.93 | PIM1 (0.86) | PIM1PIM2PIM3HPGDMAOA | |
| SCHEMBL10272939 | 0.86 | PIM1 (0.74) | PIM1PIM2HPGDMAOAMAOB | |
| SCHEMBL12961168 | 0.85 | NAT1 (0.73) | MAOARAB9ACISD1NPC1 | |
| SCHEMBL15332599 | 0.85 | MEN1 (0.73) | PIM1PIM2PIM3HPGDMAOA | |
| SCHEMBL15332601 | 0.85 | MEN1 (0.73) | PIM1PIM2PIM3HPGDMAOA | |
| SCHEMBL1125091 | 0.85 | NAT1 (0.73) | MAOARAB9ACISD1NPC1 | |
| SCHEMBL1125089 | 0.85 | NAT1 (0.73) | MAOARAB9ACISD1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
| EP-2558577-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2013-02-20 | — | — | EP | disclosed |
| WO-2011127933-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2011-10-20 | — | — | WO | disclosed |
| US-6452014-B1 | THIAZOLIDINEDIONE COMPOUNDS | GERON CORPORATION | 2002-09-17 | — | — | US | disclosed |
| US-20020120144-A1 | Telomerase inhibitors and methods of their use | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-08-29 | — | — | US | disclosed |
| WO-2002051409-A1 | TELOMERASE INHIBITORS AND METHODS OF THEIR USE | GERON CORPORATION (US) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020120144-A1 | Telomerase inhibitors and methods of their use | TERT, TERF2, POT1 | PIM1 1545/4885PIM2 2078/4885PIM3 1637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.